Compare LPCN & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPCN | CPIX |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 73.6M |
| IPO Year | 2011 | 2007 |
| Metric | LPCN | CPIX |
|---|---|---|
| Price | $7.84 | $3.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 98.3K | 95.4K |
| Earning Date | 03-10-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.18 | ★ 58.70 |
| EPS | N/A | ★ N/A |
| Revenue | $1,976,677.00 | ★ $42,010,949.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $74.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $2.52 | $1.85 |
| 52 Week High | $12.37 | $6.27 |
| Indicator | LPCN | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 46.32 |
| Support Level | $7.62 | $2.95 |
| Resistance Level | $8.35 | $3.69 |
| Average True Range (ATR) | 0.62 | 0.23 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 38.98 | 75.00 |
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.